0115 837 0503 info@aureliabio.com

Scientists at Aurelia Bioscience Ltd have decades of experience in drug discovery gained at several blue chip pharmaceutical companies including Hoffmann La Roche, Smith Kline Beecham, Glaxo-Wellcome, AstraZeneca, ICI and UCB.

They have worked in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation drug discovery phases in both cellular and non-cellular assay formats. They have experience of a wide range of technologies designed to prosecute these activities in a scalable manner whilst bringing to bear technological developments that have the ability to probe ever further into the molecular interactions from which the drugs of the future may be identified.

Research areas worked in include respiratory disease, inflammatory disease, oncology, CNS-pain, rare disorders and diabetes.

Gary brings together innovative technology from R&D partners with client projects to create synergies and novel readouts, improving assay quality and reducing client project SAR cycle times. At Aurelia Bioscience, he leverages over 30 years of pre-clinical drug discovery experience and a number of scientific papers in leading journals to aid the discovery of new chemical entities.

After gaining his Ph.D. from Edinburgh University in 1990, Gary joined Hoffmann La Roche (USA) to investigate retinoid pharmacology and the role of nuclear hormone receptors in foetal development. He then went on to work in the Lead Generation Section of Glaxo-Simth-Kline (UK) in 1995, gaining expertise in the development of cell-based assays within the CNS disease area for high throughput screening as well as novel drug discovery assay technologies and automation. After leaving GSK, Gary spent over 10 years at AstraZeneca (UK), developing novel cell-culture robotics and evaluating and implementing new assay technologies for respiratory and inflammatory diseases, before founding Aurelia Bioscience.

Allenby@aureliabio.com

Kathy researches and designs bespoke assays that support client’s projects. She is passionate about data and delivering the best assay for a drug discovery project. She is responsible for day to day operations of the business and engaging with clients at the early stages of a project. Kathy was one of the co-founders of Aurelia Bioscience with Dr Gary Allenby in 2011. The company was established with the aim of bringing their expertise in technology to the biotechnology and pharma sectors as a CRO.

The company was acquired by Charnwood Molecular Ltd a chemistry CRO in 2021 and now offers integrated drug discovery to clients.

Kathy has a degree in Biochemistry and an MSc in Neuropharmacology. She has been involved in drug discovery for almost 30 years and has held a number of positions at AstraZeneca and prior to that at SmithKline Beecham. She has spent nearly 15 years in assay development and high throughput screening groups dedicated to supporting a number of disease areas including respiratory and inflammation and neuroscience. Kathy led the implementation and automation of label-free cell-based screening (on the Epic system from Corning) within AstraZeneca.

Dodgson@aureliabio.com

Share This